AP-24567, formerly known as N-Desmethyl ponatinib, is a major metabolite of ponatinib by the action of CYP3A4. It is 4-fold less potent than ponatinib. Ponatinib (AP24534) is a BCR‐ABL tyrosine kinase inhibitor (TKI) approved by FDA for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positiveacute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially mediatedby CYP3A4.

纯度：≥98%

CAS：943319-87-7